Research Programme: JPH 367 -J-PharmaAlternative Names: JPH-367
Latest Information Update: 24 Mar 2015
At a glance
- Originator J-Pharma
- Class Small molecules
- Mechanism of Action SLC11A2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hyperuricaemia
Most Recent Events
- 25 Feb 2015 Preclinical trials in Hyperuricaemia in Japan (unspecified route) (J-Pharma pipeline, February 2015)